Acute Promyelocytic Leukemia Study
SWOG S0535: A Phase II Study Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogoamicin in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia (APL)
Protocol ID
Protocol Description
The purpose of this study is to learn about the effects of treating high-risk acute promyelocytic leukemia (APL) with chemotherapy. The chemotherapy for APL has three parts: induction therapy, consolidation therapy, and maintenance therapy. The purpose of the induction therapy is to eliminate the signs and symptoms of APL from the body. If this happens, the APL will be in "remission". Consolidation therapy and maintenance therapy are intended to make remission last as long as possible.
One of the main purposes of this trial is to study the effects, good and/or bad, of an experimental combination and schedule of chemotherapy drugs for people who have difficult-to-treat APL. This combination and schedule of chemotherapy drugs is currently the standard treatment at North Shore Long-Island Jewish Health System for patients with difficult-to-treat APL.
Eligibility Criteria
Patients with high-risk acute promyelocytic leukemia (APL)
Primary Investigator(s)
- Jonathan Kolitz, MD